Adverse drug reaction (ADRs) are unwanted effects of drug administration regardless of etiology and pathogenic mechanism. ADRs occur in about 10%-20% of all hospitalized pati ents and involve various mechanisms. Delayed type ADRs may appear after several months. Thus, periodic followup examinations are necessary. 1) According to the report of Korea Institute of Drug Safety & Risk Management (KIDS) in 2015, antiepileptic drugs (AEDs) account for 2.2% of total drugs causing ADRs ranging from nausea to skin rash to death. Leukopenia caused 2,562 of 112,418 cases (0.9%), while neutropenia caused 2,303 cases (0.8%). Among ADRs in AEDs, hematologic disorders range from thrombocytopenia or neutropenia to bone marrow failure. are at a greater risk of infection regardless of the duration. Previous studies reported hema tological side effects of carbamazepine (CBZ) at a frequency of 1:38,000-1:10,800, whereas ADRs of OXC are reportedly rare. OXC is used to treat partial and secondarily gene ralized tonic clonic seizures, and its active metabolite, monohydroxy derivative, exerts its effects on sodium channels and possibly potassium and calcium channels with a mechanism of action similar to that of CBZ and comparable efficacy but superior safety.
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According to the KIDS report, there were 212 cases of OXCinduced ADRs in patients under 18 years of age between 2011 and 2015, including 3 cases (1.4%) of hematologic side effect, 1 case of leukopenia, 1 case of neutropenia, and 1 case of thrombocytopenia. However, cases of OXCinduced side effects are possibly underestimated. 2, 3) In the current issue of the Korean Journal of Pediatrics, Jung and Yoo 10) evaluated the hematologic profile of 184 patients treated with OXC. Hematologic side effects developed in 10 of the 184 patients (5.4%) who were prescribed OXC between 2001 and 2018. Although the study was limited by its a singlecenter design, retrospective nature, and small number of cases, the 5.4% frequency of hematologic side effects of OXC indicates that they are not rare; in fact, this rate is actually higher than previous data suggested. These data provide the basis for the need for careful followup of patients treated with OXC.
